1. Digestive System tumours . Gastric adenocarcinoma. In: the WHO classification of tumours Editorial Board (ed) WHO Classification of Tumours 5th ed. Geneva:WHO, Chapter 3, pp. 85–95
Google Scholar2. Japanese Gastric Cancer Association [internet] . Kyoto (Japan): Japanese Gastric Cancer Association (2018) [Japanese Gastric Cancer Association report of national registration analysis result: surgical cases in 2009] (in Japanese). Available from: http://www.jgca.jp/entry/iganhtml/doc/2009_report.pdf
Google Scholar3. Egashira, Y, Shimoda, T, Ikegami, M. Mucin histochemical analysis of minute gastric differentiated adenocarcinoma. Pathol Int 1999; 49: 55–61.
Google Scholar | Crossref | Medline4. Kabashima, A, Yao, T, Sugimachi, K, et al. Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum Pathol 2002; 33: 80–86.
Google Scholar | Crossref | Medline5. Saito, A, Shimoda, T, Nakanishi, Y, et al. Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. Pathol Int 2001; 51: 165–171.
Google Scholar | Crossref | Medline6. Shibata, N, Watari, J, Fujiya, M, et al. Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype. Hum Pathol 2003; 34: 32–40.
Google Scholar | Crossref | Medline7. Tajima, Y, Shimoda, T, Nakanishi, Y, et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology 2001; 61: 212–220
Google Scholar | Crossref | Medline | ISI8. Cavalcanti, E, De Michele, F, Lantone, G et al. Mucin phenotype of differentiated early gastric cancer: an immunohistochemistry study supporting therapeutic decision making. Cancer Manag Res 2019; 17(11): 5047–5054.
Google Scholar | Crossref9. Molinari, C, Tedaldi, G, Rebuzzi, F et al. Early gastric cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis. Gastric Cancer 2021; 24(2):392–401.
Google Scholar | Crossref | Medline10. Yoshikawa, A, Inada Ki, K, Yamachika, T, et al. Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression. Gastric Cancer 1998; 1: 134–141.
Google Scholar | Crossref | Medline11. Wakatsuki, K, Yamada, Y, Narikiyo, et al. Clinicopathological and prognostic significance of mucin phenotype in gastric cancer. J Surg Oncol 2008; 98: 124–129
Google Scholar | Crossref | Medline12. Kim, DH, Shin, N, Kim, GH, et al. Mucin expression in gastric cancer. Arch Pathol Lab Med 2013; 137: 1047–1053.
Google Scholar | Crossref | Medline13. Wang, JY, Chang, CT, Hsieh, JS, et al. Role of MUC1 and MUC5AC expression as prognostic indicators in gastric carcinomas. J Surg Oncol 2003; 84: 253–260.
Google Scholar | Crossref14. Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma. 15th ed. (in Japanese). Tokyo: Kanehara, 2017.
Google Scholar15. Nakamoto, J, Torisu, R, Aoki, R. Clinicopathological evaluation of biological behavior of submucosal invasive gastric carcinomas: relationship among lymph node metastasis, mucin phenotype, and proliferative activity. J Med Invest 2007; 54: 99–108.
Google Scholar | Crossref | Medline16. Nakamura, T, Yao, T, Kabashima, A, et al. Loss of phenotypic expression is related to tumour progression in early gastric differentiated adenocarcinoma. Histopathology 2005; 47: 357–367.
Google Scholar | Crossref | Medline17. Koseki, K, Takizawa, T, Koike, M, et al. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer 2000; 89: 724–732.
Google Scholar | Crossref | Medline | ISI18. Han, HS, Lee, SY, Lee, KY, et al. Unclassitified mucin phenotype of gastric adenocarcinoma exhibits the highest invasiveness. J Gastroenterol Hepatol 2009; 24: 658–666.
Google Scholar | Crossref | Medline19. Osaki, M, Moriyama, M, Adachi, K, et al. Expression of RUNX3 protein in human gastric mucosa, intestinal metaplasia and carcinoma. Eur J Clin Invest 2004; 34: 605–612.
Google Scholar | Crossref | Medline20. Li, QL, Ito, K, Sakakura, C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113–124.
Google Scholar | Crossref | Medline21. Wei, D, Gong, W, Oh, SC. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 2005; 65:4809–4816.
Google Scholar | Crossref | Medline22. Voon, DC, Wang, H, Koo, JK, et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells 2012; 30 (10): 2088–2099.
Google Scholar | Crossref | Medline23. Xiangming, C, Hokita, S, Nuruki, K, et al. The expression of cadherin-catenin complex in assosiation with the clinicopathologic feature of early gastric cancer. Surg Today 1998; 28: 587–594.
Google Scholar | Crossref | Medline24. Gotoda, T, Yanagisawa, A, Sasako, M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3(4):219–225.
Google Scholar | Crossref | Medline